AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04740944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salutogenic Approach Based Interview
Description: Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
Study NCT04171011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator device
Description: The stimulator device will be used to electrically stimulate the NVB
Study NCT02399449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand sodium ferric gluconate
Description: brand product
Study NCT02399449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic sodium ferric gluconate
Description: generic product
Study NCT04197037 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.
Description: Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
Study NCT01334840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water
Description: Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal
Study NCT01334840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral water low in mineral content (control)
Description: Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal
Study NCT01801007 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Flow Re-Direction Endoluminal Device (FRED)
Study NCT03629171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT03629171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03684993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arabic, Gum
Description: natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
Study NCT03684993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice Root
Description: natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
Study NCT03684993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
Study NCT00552253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin treatment
Description: Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
Study NCT00772980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
Study NCT00772980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
Study NCT02894606 — intervention group
Intervention type: DRUG
Intervention: Thymoglobulin Induction
Description: The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
Study NCT02894606 — intervention group
Intervention type: DRUG
Intervention: Basiliximab Induction
Description: The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
Study NCT02798172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Metformin
Description: The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Screening Criteria Review
Description: The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States.
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Pre-Travel Questionnaire
Description: The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States.
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Pre-Travel Stool Specimen Collection
Description: The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study NCT04786275 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: Standard dose of 2 ug/kg after tetanic stimulation.
Study NCT04786275 — intervention group
Intervention type: OTHER
Intervention: Tetanic stimulation
Description: Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
Study NCT03874897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2
Study NCT03874897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
Study NCT02813525 — intervention group
Intervention type: OTHER
Intervention: ISI index on Doppler systolic flow in the aortic isthmus
Description: Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
Study NCT03705572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lacprodan PL20
Description: Milk protein concentrate that is high in phospholipid content (min 16%).
Study NCT03705572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo milk drink.
Study NCT00464893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catumaxomab
Description: 10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
Study NCT00464893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: catumaxomab
Description: 10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
Study NCT01706159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
Study NCT01706159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
Study NCT01567007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual counseling
Description: Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
Study NCT01567007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group counseling
Description: The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
Study NCT04381325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0254 Injection
Description: An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
Study NCT03874897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First-line systemic therapy according to physician's choice
Study NCT04875650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of Mandibular Molar using Physics Forceps
Description: Extraction of mandibular molars using physics forceps
Study NCT03886233 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid Series
Description: immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Study NCT01230801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA
Study NCT03578029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-137
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.
Study NCT03578029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.
Study NCT01494480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
Study NCT04875650 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Extraction of Mandibular Molar using Conventional Forceps
Description: Extraction of mandibular molars using conventional forceps
Study NCT01180816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Description: A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
Study NCT02288559 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection will be administered as a matching intravitreal injection of lampalizumab.
Study NCT03036345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-monitoring
Description: Monitored using both INVOS and FORE-SIGHT monitors.
Study NCT02288559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: 10 mg dose of lampalizumab administered intravitreally
Study NCT01757561 — intervention group
Intervention type: PROCEDURE
Intervention: propofol
Description: use total intravenous anesthesia with propofol
Study NCT01757561 — intervention group
Intervention type: PROCEDURE
Intervention: sevoflurane
Description: use inhalation anesthesia with sevoflurane
Study NCT03350893 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emulsion base with probiotics
Description: Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
Study NCT03350893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Emulsion base
Description: Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
Study NCT01057550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous fascial sling
Description: Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
Study NCT01057550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT
Description: Standard TVT as described by Ulmsten 1996
Study NCT01057550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvicol
Description: retropubic mid urethral sling made from Pelvicol
Study NCT04025307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bacTRL-IL-12
Description: bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
Study NCT01942291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
Study NCT06215599 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
Study NCT01848002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
Study NCT01848002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Short-Term Post-Travel Questionnaire
Description: The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel.
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Short-Term Post-Travel Stool Specimen Collection
Description: The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study NCT01811173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-physician comprehensive care
Description: Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan.
Study NCT02536066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postprandial physical activity
Description: Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
Study NCT04022408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid based cytology
Description: Liquid based cytology
Study NCT04022408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cytology
Description: Conventional cytology
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Study NCT04075422 — intervention group
Intervention type: DRUG
Intervention: Bezlotoxumab Injection [Zinplava]
Description: Treatment with bezlotoxumad according to the routine clinical practices
Study NCT01567007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
Study NCT01579071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 or room air insufflation during ESD for gastric tumor
Description: CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
Study NCT00336882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
Study NCT00336882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
Study NCT03742622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03742622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX. Condition with an acute exercise set in the middle of the morning
Description: EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals